Profound Medical Corp. (PRN.TO) TSX
Currency In CAD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CAD
Address
2400 Skymark Avenue
Mississauga, ON L4W 5K5
Canada
Phone
647 476 1350
Sector
Healthcare
Industry
Medical - Devices
Employees
142
First IPO Date
July 10, 2018
| Name | Title | Pay | Year Born |
| Arun Swarup Menawat | Chairman of the Board & Chief Executive Officer | 1.41M | 1955 |
| Thomas Tamberrino | Chief Commercial Officer | 541,463 | 1980 |
| Rashed Dewan | Chief Financial Officer | 669,068 | 1968 |
| Mathieu Burtnyk | President | 679,783 | 1982 |
| Levant Tinaz | Software Developer | 0 | N/A |
| Stephen Kilmer | Investor Relations | 0 | N/A |
| Matthew Sobczyk | Assistant Corporate Controller | 0 | N/A |
Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.